Inventiva (NASDAQ:IVA) Now Covered by Analysts at TD Cowen

TD Cowen began coverage on shares of Inventiva (NASDAQ:IVA) in a research note issued to investors on Friday, Marketbeat Ratings reports. The firm issued a buy rating and a $10.00 price target on the stock.

Several other research analysts have also commented on IVA. UBS Group started coverage on shares of Inventiva in a research note on Tuesday, November 12th. They set a “neutral” rating and a $3.00 price target on the stock. Stifel Nicolaus decreased their target price on shares of Inventiva from $20.00 to $17.00 and set a “buy” rating on the stock in a research report on Friday, November 22nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $13.00 target price on shares of Inventiva in a research note on Thursday, January 30th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $12.60.

Inventiva Stock Performance

Shares of Inventiva stock opened at $2.84 on Friday. The business has a fifty day simple moving average of $2.33 and a 200-day simple moving average of $2.36. Inventiva has a fifty-two week low of $1.53 and a fifty-two week high of $4.50.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.